RSWM
RLMD icon

Robertson Stephens Wealth Management’s Relmada Therapeutics RLMD Stock Holding History

Robertson Stephens Wealth Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Hold
25,000
– – ﹤0.01% 623
2026
Q1 		$174K Hold
25,000
– – ﹤0.01% 591
2025
Q4 		$121K Hold
25,000
– – ﹤0.01% 618
2025
Q3 		$50.3K Hold
25,000
– – ﹤0.01% 526
2025
Q2 		$15K Hold
25,000
– – ﹤0.01% 550
2025
Q1 		$6.75K Hold
25,000
– – ﹤0.01% 544
2024
Q4 		$13K Buy
+25,000
New +$61K ﹤0.01% 557

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Robertson Stephens Wealth Management's RLMD Position: Q2 2026 in Review

Robertson Stephens Wealth Management held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 25,000 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #623.

Robertson Stephens Wealth Management first reported a position in RLMD in Q4 2024 and has held it in 7 quarters since. The position peaked at $174K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Robertson Stephens Wealth Management held 25,000 shares of Relmada Therapeutics worth $173K as of Q2 2026.
  • Robertson Stephens Wealth Management left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Robertson Stephens Wealth Management's portfolio in Q2 2026, its #623 holding.
  • Robertson Stephens Wealth Management first reported a position in Relmada Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Robertson Stephens Wealth Management's Relmada Therapeutics position peaked at $174K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Robertson Stephens Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.